HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance - PubMed (original) (raw)
Review
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance
M Campoli et al. Oncogene. 2008.
Abstract
Changes in classical and nonclassical HLA class I as well as HLA class II antigens have been identified in malignant lesions. These changes, which are described in this review are believed to play a major role in the clinical course of the disease since both HLA class I and class II antigens are critical to the interaction between tumor cells and components of both innate and adaptive immune system. Abnormalities in HLA antigen expression in malignant cells, which range in frequency from 0-90%, are caused by distinct mechanisms. They include defects in beta(2)-microglobulin (beta(2)m) synthesis, loss of the gene(s) encoding HLA antigen heavy chain(s), mutations, which inhibit HLA antigen heavy chain transcription or translation, defects in the regulatory mechanisms, which control HLA antigen expression and/or abnormalities in one or more of the antigen processing, machinery (APM) components. More recently, epigenetic events associated with tumor development and progression have been found to underlie changes in HLA antigen, APM component, costimulatory molecule and tumor antigen (TA) expression in malignant cells. The types of epigenetic modifications that may occur in normal and malignant cells as well as their role in changes in HLA antigen expression by malignant cells have been reviewed. The epigenetic events associated with alterations in HLA antigen expression may be clinically relevant as, in some cases, they have been shown to impair the recognition of tumor cells by components of the adaptive immune system. The functional relevance and potential clinical significance of these epigenetic alterations have been addressed. Finally, unlike genetic alterations, epigenetic modifications can, in some cases, be reversed with pharmacologic agents that induce DNA hypomethylation or inhibit histone deacetylation. Therefore, strategies to overcome epigenetic modifications underlying changes in HLA antigen expression in malignant cells have been discussed.
Figures
Figure 1. Molecular mechanisms underlying the abnormal HLA class I antigen phenotypes identified in malignant cells
Intracellular protein antigens, which are mostly endogenous, are marked for ubiquitination within the cytosol and subsequently degraded into peptides by proteasomal cleavage. Once generated, peptides are transported into the endoplasmic reticulum through the dimeric transporter associated with antigen processing, TAP1 and TAP2. Nascent, HLA class I heavy chains are synthesized in the ER and associate with the chaperone immunoglobulin heavy chain binding protein (BiP), a universal ER chaperone involved in the translation and insertion of proteins into the ER. Following insertion into the ER, the HLA class I heavy chain associates with antigen processing machinery components (APM), i.e., calnexin, ERp57, calreticulin and tapasin. The trimeric HLA class I‐b2m‐peptide complex is then transported to the plasma membrane where it plays a major role in the interactions between target cells and T cells. (A) Total HLA class I (HLA-A, -B and -C) loss is caused by loss of β2m expression and/or function; (B) Selective HLA class I allospecificity loss is caused by loss of the gene(s) which encode(s) the lost HLA class I allele(s) or by mutations which inhibit their transcription or translation; (C) Total loss of one HLA class I haplotype is caused by total or partial loss of one copy of chromosome 6 which encodes the genes for HLA class I heavy chains; (D) Total HLA class I downregulation is caused by loss or downregulation of APM components; (E) Selective HLA class I locus downregulation may be caused by locus-specific defects in HLA class I gene transcription.
Figure 2. Epigenetic modulations underlying abnormal gene expression identified in malignant cells
In the nucleus the DNA double helix is wrapped around histone octamers to form nucleosomes, the basic structure of DNA inside the nucleus. (A) Modification of histones through methylation (-CH3) or acetlylation (-OCCH3) affects gene expression by targeting various protein complexes to DNA, resulting either in an open chromatin structure ready for expression or in a closed chromatin configuration that is impermeable to transcription factors and associated with gene silencing. (B) DNA methylation refers to the enzymatic addition of a methyl group to the 5 position of cytosine incorporated into DNA. In mammals, methylation is largely limited to cytosines that are part of the symmetrical dinucleotide CpG. A switch from unmethylated to methylated CpG island results in permanent loss of gene expression. (C) RNA interference (RNAi) is a post-transcriptional mechanism whereby gene expression is suppressed by RNA degradation, triggered by short stretches of complementary RNA. This process is a prominent mechanism of epigenetic regulation in plants and other organisms, where it plays roles varying from genome defense to chromosomal structure.
Figure 3. Frequency of classical HLA class I downregulation and of non-classical HLA class I antigen and HLA class II antigen expression in malignant lesions of different embryological origin
The most common types of solid tumors for which more than 50 primary lesions have been analyzed for (A) classical, (B) non-classical HLA class I and (C) HLA class II expression are shown. Data has been adapted from [6,11-15,47-62]. BCC, cutaneous basal cell carcinoma, ESO, esophageal carcinoma; HNSCC, head and neck squamous cell carcinoma; MM, malignant melanoma; RCC, renal cell carcinoma; SCC, squamous cell carcinoma; UM, uveal melanoma. (■) Indicates total HLA class I antigen loss and/or downregulation; () indicates selective HLA class I allospecificity loss.
Figure 4. Molecular mechanisms underlying the functional properties of HLA expression by malignant cells
(A) Once the classical HLA class I-β2m-peptide complex is transported to the plasma membrane it plays a major role in the interactions between target cells and (a) activation of peptide-specific CTL through TCR; and (b) inhibition of T cell subpopulations through inhibitory receptors KIR. (B) In contrast to classical HLA class I, the non-classical HLA class I, HLA-G, inhibits CTL, CD4(+) T cells and NK cells through its interaction with the NK cells receptor CD94/NKG2. (C) HLA class II expression by tumor cells may be potentially beneficial to TA-specific immune responses through their interaction with CD4(+) T cells, resulting in the activation of (1) CD4(+) T cell-mediated killing, (2) macrophage through release of Th1 cytokines; (2) B cells and eosinophils through release of Th2 cytokines, and (4) CTL through release of Th1 cytokines.
Similar articles
- Evolution of studies of HLA class I antigen processing machinery (APM) components in malignant cells.
Sabbatino F, Schwab JH, Ferrone S, Ferrone CR. Sabbatino F, et al. Clin Transpl. 2013:453-63. Clin Transpl. 2013. PMID: 25095541 Review. - Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions.
Chang CC, Campoli M, Ferrone S. Chang CC, et al. Adv Cancer Res. 2005;93:189-234. doi: 10.1016/S0065-230X(05)93006-6. Adv Cancer Res. 2005. PMID: 15797448 Review. - The role of classical and non-classical HLA class I antigens in human tumors.
Bukur J, Jasinski S, Seliger B. Bukur J, et al. Semin Cancer Biol. 2012 Aug;22(4):350-8. doi: 10.1016/j.semcancer.2012.03.003. Epub 2012 Mar 24. Semin Cancer Biol. 2012. PMID: 22465194 Review. - HLA class I defects in malignant lesions: what have we learned?
Chang CC, Campoli M, Ferrone S. Chang CC, et al. Keio J Med. 2003 Dec;52(4):220-9. doi: 10.2302/kjm.52.220. Keio J Med. 2003. PMID: 14748474 Review.
Cited by
- iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens.
Englisch A, Hayn C, Jung S, Heitmann JS, Hackenbruch C, Maringer Y, Nelde A, Wacker M, Denk M, Zieschang L, Kammer C, Martus P, Salih HR, Walz JS. Englisch A, et al. Front Oncol. 2024 Aug 26;14:1441625. doi: 10.3389/fonc.2024.1441625. eCollection 2024. Front Oncol. 2024. PMID: 39252947 Free PMC article. - Peptide-stimulated T cells bypass immune checkpoint inhibitor resistance and eliminate autologous microsatellite instable colorectal cancer cells.
Schwarz S, Su Z, Krohn M, Löffler MW, Schlosser A, Linnebacher M. Schwarz S, et al. NPJ Precis Oncol. 2024 Jul 29;8(1):163. doi: 10.1038/s41698-024-00645-3. NPJ Precis Oncol. 2024. PMID: 39075115 Free PMC article. - Identification of RNA-binding protein hnRNP C targeting the 3'UTR of the TAP-associated glycoprotein tapasin in melanoma.
Wang Y, Seliger B. Wang Y, et al. Oncoimmunology. 2024 Jun 27;13(1):2370928. doi: 10.1080/2162402X.2024.2370928. eCollection 2024. Oncoimmunology. 2024. PMID: 38948930 Free PMC article. - Azacitidine and gemtuzumab ozogamicin as post-transplant maintenance therapy for high-risk hematologic malignancies.
Kaito S, Najima Y, Sadato D, Hirama C, Kishida Y, Nagata A, Konishi T, Yamada Y, Kurosawa S, Yoshifuji K, Shirane S, Shingai N, Toya T, Shimizu H, Haraguchi K, Kobayashi T, Harada H, Okuyama Y, Harada Y, Doki N. Kaito S, et al. Bone Marrow Transplant. 2024 Aug;59(8):1169-1175. doi: 10.1038/s41409-024-02311-5. Epub 2024 May 23. Bone Marrow Transplant. 2024. PMID: 38783125 - Chondroitin sulfate proteoglycan 4: An attractive target for antibody-based immunotherapy.
Kurokawa T, Imai K. Kurokawa T, et al. Proc Jpn Acad Ser B Phys Biol Sci. 2024;100(5):293-308. doi: 10.2183/pjab.100.019. Proc Jpn Acad Ser B Phys Biol Sci. 2024. PMID: 38735753 Free PMC article. Review.
References
- Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991–998. - PubMed
- Campoli M, Ferrone S, Zea AH, Rodriguez PC, Ochoa AC. Mechanisms of tumor evasion. Cancer Treat Res. 2005;123:61–88. - PubMed
- Chang CC, Ferrone S. NK cell activating ligands on human malignant cells: molecular and functional defects and potential clinical relevance. Semin Cancer Biol. 2006;16:383–92. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials